Chloroquine-resistant Plasmodium falciparum malaria prevention

Chloroquine-resistant *Plasmodium falciparum* malaria prevention refers to chemoprophylaxis aimed at protecting individuals—most commonly travelers, military personnel, and non-immune residents in endemic regions—from mosquito-borne infection caused by strains of *Plasmodium falciparum* that harbor mutations, such as in the *pfcrt* gene, conferring resistance to 4-aminoquinoline therapies

Chloroquine-resistant *Plasmodium falciparum* malaria prevention refers to chemoprophylaxis aimed at protecting individuals—most commonly travelers, military personnel, and non-immune residents in endemic regions—from mosquito-borne infection caused by strains of *Plasmodium falciparum* that harbor mutations, such as in the *pfcrt* gene, conferring resistance to 4-aminoquinoline therapies

Transmitted via the bite of infected female *Anopheles* mosquitoes, the protozoan parasite first infects hepatocytes before invading and destroying host erythrocytes, causing vascular sequestration and microvascular obstruction across multiple organ systems

Transmitted via the bite of infected female *Anopheles* mosquitoes, the protozoan parasite first infects hepatocytes before invading and destroying host erythrocytes, causing vascular sequestration and microvascular obstruction across multiple organ systems

Clinically, breakthrough infection presents with cyclic paroxysms of high fevers, chills, diaphoresis, headache, and severe hemolytic anemia, with a high propensity to rapidly progress to life-threatening complications such as cerebral malaria, acute respiratory distress syndrome, metabolic acidosis, and multi-organ failure

Consequently, prevention in areas harboring these resistant strains requires alternative prophylactic regimens to block hepatic or erythrocytic schizogony